Skip to content
Review Open access

Patterns of treatment-related adverse events and treatment discontinuation in phase III oncology clinical trials.

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

466 Background: Treatment-related adverse events (TRAEs) are a common cause of discontinuation in cancer clinical trials. Although TRAEs are routinely documented, the relative contributions of patients (pts), clinicians, and protocol-mandated requirements to these decisions remain poorly characterized. We sought to characterize TRAEs and identify the decision maker responsible for toxicity-related study treatment discontinuation in a cohort of trial participants. Methods: We performed a retrospective review of pts treated on Phase 3 cancer clinical trials in the Mount Sinai Health System from January 2021 and October 2025. Pts, including those who discontinued study participation due to a TRAE, were identified using a central clinical trial database and clinical and demographic data were obtained using the electronic medical record (EMR). Each toxicity-related discontinuation was categorized as protocol-mandated, clinician-directed, pt-directed, or a shared pt-clinician decision. In unclear cases, the study protocol or a member of the study team was consulted. TRAEs were classified by toxicity category and severity according to CTCAE version 5.0. Descriptive statistics were used to summarize patterns in discontinuation. Results: Among 306 pts enrolled in phase III oncology clinical trials, 34 (11.1%) discontinued study participation due to a TRAE. Within this population, nearly half were on trials of targeted therapies (47.1%), followed by immunotherapy (23.5%), combination therapy (11.8%), endocrine therapy (11.8%), and antibody-drug conjugates (5.9%). The median number of prior systemic therapy lines was 1 (range, 0–5), and 47.1% of pts had received no prior systemic therapy. Median treatment duration was 119 days (range, 6–675 days), with 70.6% of discontinuations occurring within the first six months of treatment. The most common toxicities leading to discontinuation were gastrointestinal (7/34, 20.6%) and constitutional (6/34, 17.6%), followed by hematologic and pneumonitis (4/34 each, 11.8%). Grade 1, 2, 3, and 4 TRAEs leading to treatment discontinuation occurred in 5.9% (n=2), 47.1% (n=16) 41.2% (n=14) and 5.9% (n=2) of cases, respectively. Discontinuation was equally likely to be pt-directed or protocol-mandated (12/34 each, 35.3%), followed by clinician-directed (6/34, 17.6%). Four pts (11.8%) discontinued study therapy following a shared pt-clinician decision. No clinical or demographic features were significantly associated with an increased likelihood of TRAE-related study withdrawal. Conclusions: Among pts who discontinued phase 3 oncology trials due to TRAEs, pt-directed discontinuation occurred at the same frequency as protocol-required discontinuation. These results demonstrate the importance of proactive toxicity management and shared-decision making in limiting TRAE-driven study therapy discontinuation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.